Your browser is no longer supported. Please, upgrade your browser.
AzurRx BioPharma, Inc.
Index- P/E- EPS (ttm)-2.21 Insider Own1.03% Shs Outstand74.44M Perf Week-5.08%
Market Cap70.89M Forward P/E- EPS next Y-0.28 Insider Trans0.00% Shs Float73.00M Perf Month20.59%
Income-66.50M PEG- EPS next Q-0.07 Inst Own4.10% Short Float3.28% Perf Quarter-43.65%
Sales- P/S- EPS this Y-116.80% Inst Trans61.23% Short Ratio0.69 Perf Half Y14.18%
Book/sh0.46 P/B1.89 EPS next Y3.40% ROA-487.80% Target Price- Perf Year-6.48%
Cash/sh0.15 P/C5.91 EPS next 5Y- ROE- 52W Range0.65 - 2.63 Perf YTD-10.54%
Dividend- P/FCF- EPS past 5Y-19.00% ROI- 52W High-67.28% Beta1.52
Dividend %- Quick Ratio3.70 Sales past 5Y- Gross Margin- 52W Low32.38% ATR0.06
Employees12 Current Ratio3.70 Sales Q/Q- Oper. Margin- RSI (14)48.92 Volatility4.87% 6.76%
OptionableNo Debt/Eq0.02 EPS Q/Q-392.90% Profit Margin- Rel Volume0.31 Prev Close0.87
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume3.48M Price0.86
Recom2.20 SMA200.97% SMA500.46% SMA200-12.32% Volume772,321 Change-0.83%
Jan-06-21Downgrade Dawson James Buy → Neutral
Jun-11-19Initiated National Securities Buy $9
Oct-17-18Initiated Oppenheimer Outperform $6
Jul-24-17Initiated H.C. Wainwright Buy $8
Jun-08-21 07:00AM  
Jun-07-21 07:00AM  
Jun-04-21 02:01PM  
May-19-21 07:30AM  
May-14-21 03:00PM  
May-13-21 08:49AM  
May-12-21 07:30AM  
May-11-21 08:30AM  
May-10-21 07:00AM  
Apr-15-21 07:30AM  
Apr-13-21 08:30AM  
Apr-06-21 09:41AM  
Apr-01-21 06:30AM  
Mar-31-21 04:35PM  
Mar-22-21 07:00AM  
Mar-16-21 07:00AM  
Mar-10-21 07:00AM  
Mar-08-21 08:00AM  
Mar-02-21 07:00AM  
Feb-24-21 07:00AM  
Feb-16-21 07:00AM  
Feb-09-21 06:30AM  
Feb-08-21 08:00AM  
Jan-28-21 07:00AM  
Jan-26-21 07:00AM  
Jan-22-21 10:18AM  
Jan-21-21 10:34AM  
Jan-12-21 08:30AM  
Jan-08-21 09:00AM  
Jan-07-21 08:00AM  
Jan-06-21 08:00AM  
Jan-05-21 08:00AM  
Jan-04-21 07:00AM  
Nov-30-20 08:00AM  
Nov-24-20 08:17AM  
Nov-17-20 08:00AM  
Nov-10-20 08:00AM  
Oct-29-20 12:05PM  
Oct-21-20 08:00AM  
Oct-14-20 08:00AM  
Oct-07-20 08:00AM  
Sep-15-20 08:00AM  
Aug-31-20 06:12PM  
Aug-26-20 06:42AM  
Aug-17-20 08:00AM  
Aug-13-20 08:00AM  
Aug-12-20 03:43PM  
Aug-11-20 04:01PM  
Aug-05-20 11:04AM  
Jul-27-20 05:22AM  
Jul-22-20 08:20AM  
Jul-21-20 08:00AM  
Jul-20-20 08:00AM  
Jun-01-20 05:45AM  
May-29-20 03:08PM  
May-07-20 08:00AM  
May-05-20 08:00AM  
May-04-20 06:45AM  
Apr-30-20 08:00AM  
Apr-29-20 08:00AM  
Apr-21-20 08:00AM  
Apr-20-20 08:00AM  
Apr-16-20 02:00PM  
Apr-15-20 08:00AM  
Apr-09-20 10:30AM  
Apr-01-20 12:00PM  
Mar-18-20 08:00AM  
Mar-02-20 08:00AM  
Feb-18-20 08:00AM  
Feb-03-20 10:10AM  
Jan-13-20 08:00AM  
Jan-12-20 05:05PM  
Jan-09-20 07:22PM  
Jan-06-20 08:00AM  
Jan-03-20 08:00AM  
Nov-26-19 11:35AM  
Nov-14-19 08:00AM  
Oct-22-19 08:00AM  
Oct-17-19 12:30PM  
Oct-15-19 07:30AM  
Oct-10-19 07:30AM  
Sep-27-19 08:30AM  
Sep-25-19 08:57AM  
Aug-28-19 01:15PM  
AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was incorporated in 2014 and is headquartered in Delray Beach, Florida.